Editorials

Overview

In our editorial section, we delve into the evolving landscape of cutaneous oncology, offering critical analyses and insights that reflect the latest developments in the field. Each piece is crafted by esteemed authors whose opinions enrich our understanding but do not necessarily echo the consensus of the Journal of Cutaneous Oncology or its associated entities. These editorials serve to foster a deeper discourse, challenge prevailing assumptions, and highlight innovative approaches within the skin cancer community.

Volume 2 Issue 1

Should Ipilimumab Be the New “Standard” for Refractory MCC?

In this editorial, we discuss the role of ipilimumab in anti-PD-1 refractory Merkel cell carcinoma. This topic was presented at the Third International Symposium for MCC in Houston, Texas on May 4th 2024.

May 11, 2024

David Michael Miller MD, PhD

Tumor-Infiltrating Lymphocyte Therapy Receives FDA Approval

In this editorial, we reflect on the recent approval of the first cellular therapy for melanoma.

May 1, 2024

Jennifer Strong, David Michael Miller MD, PhD, Isaac Brownell MD, PhD